Psoriasis is an autoimmune disease that ingeminates itself with the repeated proliferation of keratinocytes. It globally strikes a 2-5 % population on an average. Management of psoriasis remains a daunting task with various challenges influencing treatment, such as patient conformity and adherence to therapy, delicate patient profiles, psychological aspects, and skin as a barrier to topical delivery.

This was a review published in Current Drug Safety, of research data related to the existing and upcoming therapies for psoriasis treatment, several nanocarriers, existing marketed formulations, and detailed description of phytopharmaceuticals with their mechanism.

The findings revealed that topical therapy is the mainstay treatment option with limited adverse effects. Biological therapy has reformed conventional psoriasis treatment by being more efficacious and has increased patient acceptance due to decreased adverse events. Nanoformulations present an edge over conventional therapy due to improved anti-psoriatic effect and decreased side effects. While phyto-pharmaceuticals act as a complementary and alternative therapy for diminishing psoriasis symptoms.

It was inferred that a rationalized cost-effective patient compliant therapy is required for effective management and complete cure of psoriasis.

Source: Current Drug Safety. 2020;15(2):82-104. doi: 10.2174/1574886315666200128095958.